Symptoms of overdose include coma, drowsiness, loss of muscle control, severely impaired breathing, shock, sluggishness, and unresponsiveness. There have been a case of death resulting from oral ingestion of 12 g of meprobamate. One case study reports the consumption of 40 g of meprobamate resulting in successful survival.
A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603) Meprobamate is a controlled substance in the U.S.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. |
| Hydrocodone | Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. |
| Magnesium sulfate | The therapeutic efficacy of Meprobamate can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Meprobamate may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. |
| Mirtazapine | Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. |
| Orphenadrine | Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. |
| Pramipexole | Meprobamate may increase the sedative activities of Pramipexole. |
| Ropinirole | Meprobamate may increase the sedative activities of Ropinirole. |
| Rotigotine | Meprobamate may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Meprobamate. |
| Suvorexant | Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. |
| Thalidomide | Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Yohimbine | The therapeutic efficacy of Meprobamate can be increased when used in combination with Yohimbine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Meprobamate. |
| Sodium oxybate | Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Ethanol | Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. |
| Zimelidine | The risk or severity of adverse effects can be increased when Meprobamate is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Meprobamate is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Meprobamate is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Meprobamate is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Meprobamate is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Meprobamate is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Meprobamate is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Meprobamate is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Meprobamate is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Meprobamate is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Meprobamate is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Meprobamate is combined with Escitalopram. |
| Milnacipran | The risk or severity of adverse effects can be increased when Meprobamate is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Meprobamate is combined with Desvenlafaxine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Meprobamate is combined with Levomilnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when Meprobamate is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Meprobamate is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Meprobamate is combined with Alaproclate. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Meprobamate is combined with Cyproheptadine. |
| Propiomazine | The risk or severity of CNS depression can be increased when Meprobamate is combined with Propiomazine. |
| Zopiclone | The risk or severity of adverse effects can be increased when Meprobamate is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Meprobamate. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Meprobamate. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Meprobamate. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Meprobamate. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Meprobamate. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Meprobamate. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Meprobamate. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Meprobamate. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with Meprobamate. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with Meprobamate. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with Meprobamate. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with Meprobamate. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with Meprobamate. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with Meprobamate. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with Meprobamate. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with Meprobamate. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with Meprobamate. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with Meprobamate. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Meprobamate. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Meprobamate. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with Meprobamate. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with Meprobamate. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with Meprobamate. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with Meprobamate. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Meprobamate. |
| Thiethylperazine | The risk or severity of CNS depression can be increased when Meprobamate is combined with Thiethylperazine. |
| Palonosetron | The risk or severity of CNS depression can be increased when Meprobamate is combined with Palonosetron. |
| Dexbrompheniramine | The risk or severity of CNS depression can be increased when Meprobamate is combined with Dexbrompheniramine. |
| Metocurine iodide | The risk or severity of CNS depression can be increased when Meprobamate is combined with Metocurine iodide. |
| Secobarbital | The risk or severity of CNS depression can be increased when Meprobamate is combined with Secobarbital. |
| Methocarbamol | The risk or severity of CNS depression can be increased when Meprobamate is combined with Methocarbamol. |
| Triprolidine | The risk or severity of CNS depression can be increased when Meprobamate is combined with Triprolidine. |
| Meperidine | The risk or severity of CNS depression can be increased when Meprobamate is combined with Meperidine. |
| Metharbital | The risk or severity of CNS depression can be increased when Meprobamate is combined with Metharbital. |
| Quinine | The risk or severity of CNS depression can be increased when Meprobamate is combined with Quinine. |
| Methohexital | The risk or severity of CNS depression can be increased when Meprobamate is combined with Methohexital. |
| Gallamine triethiodide | The risk or severity of CNS depression can be increased when Meprobamate is combined with Gallamine triethiodide. |
| Entacapone | The risk or severity of CNS depression can be increased when Meprobamate is combined with Entacapone. |
| Oxycodone | The risk or severity of CNS depression can be increased when Meprobamate is combined with Oxycodone. |
| Dextromethorphan | The risk or severity of CNS depression can be increased when Meprobamate is combined with Dextromethorphan. |
| Mephenytoin | The risk or severity of CNS depression can be increased when Meprobamate is combined with Mephenytoin. |
| Cisatracurium | The risk or severity of CNS depression can be increased when Meprobamate is combined with Cisatracurium. |
| Fenfluramine | The risk or severity of CNS depression can be increased when Meprobamate is combined with Fenfluramine. |
| Mazindol | The risk or severity of CNS depression can be increased when Meprobamate is combined with Mazindol. |
| Fluticasone propionate | The risk or severity of CNS depression can be increased when Meprobamate is combined with Fluticasone propionate. |
| Lisuride | The risk or severity of CNS depression can be increased when Meprobamate is combined with Lisuride. |
| Ethosuximide | The risk or severity of CNS depression can be increased when Meprobamate is combined with Ethosuximide. |
| Thiopental | The risk or severity of CNS depression can be increased when Meprobamate is combined with Thiopental. |
| Cisapride | The risk or severity of CNS depression can be increased when Meprobamate is combined with Cisapride. |
| Butorphanol | The risk or severity of CNS depression can be increased when Meprobamate is combined with Butorphanol. |